Therapeutic anti-diabetic peptides (ADPs) are an emerging class of clinically-relevant biologics with the potential to manage glucose (glycaemic) levels. However, the majority of existing computational pipelines are either narrowly focused or unverified. Here, we present a principled, end-to-end, and provenance-aware framework for the de novo generation, filtering and classification of ADPs. In terms of design, candidate peptides are derived from three complementary strategies: guided modification of functional motifs, recombination of conserved bioactive fragments, and a hybrid generative engine. Candidates are then subjected to biochemical triage (net charge, hydrophobicity, Boman index), homology screening, and APD-style predictors/calculators. For classification, we use a blend of (1) interpretable biochemical descriptors (net charge, hydrophobicity, Boman index), and (2) sequence-derived representations learned by a CNN-with-attention backbone, to parse local motifs and longer-range context. Classifier heads are automatically tuned with an Optimized Tree-structured Parzen Estimator (OptimizedTPE). Training used 238 experimentally validated ADPs with homology-aware splits (Train/Val/Internal-Test positives: 167/24/47) and a curated negative pool at a 2:1 ratio; additionally, Train-only weak-label augmentation added 412 screened positives (and matched negatives) for robustness. We report an evaluation on an independent, external panel of 180 peptides, fully disjoint from the training data in both source and time. On this unseen set, the model achieves ≈ 98.75% accuracy (F1 ≈ 0.985, precision ≈ 0.99, recall ≈ 0.98, specificity ≈ 0.99, ROC AUC ≈ 0.99). This suggests high sensitivity to true ADPs while tightly controlling false positives in the setting of realistic class imbalance. Taken together, these results make the framework a candidate for a reproducible, biologically-grounded, in silico screening layer for metabolic peptide therapeutics.
Asl et al. (Thu,) studied this question.